PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP NN Shah; PL Zinzani; TA Eyre; K Izutsu; AJ Alencar; K Patel; T Munir; DE Tsai; ML Wang; LYGN Presenter;

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY JR Brown; JA Woyach; K Patel; TA Eyre; Cy Cheah; P Ghia; W Jurczak; P Abada; WG Wierda; GFPN Presenter;

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY RRBN Presenter; N Shah; A Alencar; J Gerson; M Patel; W Jurczak; K Patel; A Mato; C Cheah; M Wang;